Information Provided By:
Fly News Breaks for May 4, 2016
REGN
May 4, 2016 | 08:07 EDT
RBC Capital says that data showed that Regeneron's Eylea improved the condition of Diabetic Macular Edema, or DME, patients who did not respond to other drugs. The firm thinks that Regeneron should be as effective in treating DME as it was in treating wet AMD. RBC Capital believes that the company "can innovate around" the reimbursement obstacles facing Eylea. It keeps a $668 price target and Outperform rating on the shares.
News For REGN From the Last 2 Days
REGN
REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.